Industry News

The new OS 4 from Oertli

Next generation surgical platform

Oertli have launched the new OS 4, which the company say is the next generation of their OS 4 surgical platform for retinal, glaucoma and cataract surgery.

“The highlights of the next OS 4 generation undoubtedly include the two Power LED light sources with 45% more power and extended control range for even more application possibilities, as well as the high-resolution contrast viewing by means of the Power LED Plus,” said a company spokeswoman.

“The integrated endo laser no longer requires manual operation thanks to the fully automated laser user protection filter,” according to Oertli. “The multifunctional pedal offers over 100 setting options and thus the preferred control for every surgeon. The phaco test is performed in record time and massively speeds up a user-friendly preparation for surgery. In general, the new OS 4 ensures speed in the operating theatre – without compromising comfort or safety.” www.oertli-instruments.com

GROWTH MILESTONES

LENSAR achieved significant growth milestones during 2020, including an increase in global market share from 13 to 16%, a 10% increase in customer installed base and a 15% increase in procedure volume in their two largest markets, according to the company. “We maintained our leading laser system utilisation position with an average of 430 procedures performed per laser vs. 232 with competitive systems. These successes are a testament to our dedication to bringing ophthalmic surgeons the most advanced and beneficial laser system available today,” said Nick Curtis, Chief Executive Officer of LENSAR. “I am also pleased to report that we remain on track to file the 510K application in the first quarter of 2022 and launch ALLY later that year,” said Mr Curtis. www.lensar.com NIDEK will mark its 50th anniversary on 8 August, 2021 with a new logo, the first time that the company has renewed its logo since its establishment. While the new logo continues to use the image of an eye, the company says that the elegant lines shaped like an “N” express the growth of the company.

NIDEK President and CEO Mr Motoki Ozawa, said: “Since our foundation in 1971, we have been operating globally in three fields, ophthalmology and optometry, lens edging and coating based on our three pillars: bringing invisible to visible, visible to recognition and our desire to enhance the eye with our products. The growth curve in our logo represents the prosperity of both our customers and NIDEK,” said Mr Ozawa. https://www.nidek-intl.com/50th

NEWS IN BRIEF

100% SOLAR POWER

Johnson & Johnson Vision has announced that its ACUVUE global headquarters in Jacksonville, USA, will run on 100% solar power after agreeing a deal with JEA of Northwest Florida. The deal, which goes into effect in 2022, will help Johnson & Johnson Vision meet its renewable electricity target and means that all ACUVUE brand contact lenses will be made using 100% renewable electricity, said a Johnson & Johnson spokesperson.

As part of the new ACUVUE® sustainability resources, the brand is also encouraging contact lens wearers not to flush their lenses down the toilet or sink to prevent them finding their way into streams, rivers and oceans. www.acuvue.com/sustainability

MEDICAL AFFAIRS APPOINTMENT

Santen EMEA has announced the appointment of Dr Ioana Grobeiu as Vice President, Medical Affairs. With over 20 years of experience in pharmaceuticals, Ioana will lead the medical affairs strategy and report to Luis Iglesias, President and Head of Santen EMEA, said the company.

“We are delighted to welcome Dr Grobeiu as our new Vice President of Medical Affairs EMEA. Ioana’s breadth and depth of experience will be invaluable as we continue to collaborate with the ophthalmology community to protect the precious sense of sight,” said Mr Iglesias. www.santen.com

US HEADQUARTERS

The ZEISS Innovation Center in Northern California is the new US headquarters for Carl Zeiss Meditec, Inc. The company say that this longterm commitment to the US market is crucial and strongly supports exciting new innovations developed in close collaboration with partners from industry, research, and local communities to benefit customers.

“The new Center serves as a global beacon for high technology and digital innovation, and it’s through this and ZEISS’ global market presence that we continue our commitment to the development of advanced technologies, creating the clinical solutions and milestones,” said a company spokesperson. www.zeiss.com